X

Trial Profile

A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 11 Feb 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palbociclib (Primary) ; Goserelin; Letrozole; Trastuzumab
Indications Advanced breast cancer; Early breast cancer
Focus Therapeutic Use
Acronyms PALTAN

Most Recent Events

09 Oct 2020 Status changed from recruiting to discontinued.
31 Jul 2019 Planned End Date changed from 31 May 2020 to 31 Dec 2021.
31 Jul 2019 Planned primary completion date changed from 31 May 2020 to 31 Oct 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com